Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03429621
Other study ID # OBG-2560-05148
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 8, 2018
Est. completion date March 31, 2019

Study information

Verified date February 2020
Source Chiang Mai University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Tubal ligation is an everyday procedure for permanent female sterilization. It is usually performed after a vaginal delivery. Minilaparotomy is generally performed by doing small incision at infraumbilical area. This minimal access surgery requires adequate operative field exposure. Bowel interference, which obscures visualization of the operative field has been recognized as one of the major obstacles during this procedure. We found problems while doing surgery in small space and one of them is bowel interferance which obscures vision. This could lead to prolonged operation and complications. Simethicone is an antifoaming agent that use in bowel preparation prior to various procedures including laparoscopy, colonoscopy, endoscopy, and open major abdominal operations. Simethicone is proven to break the bubble and reduce intraluminal gas. This effect could result in reduction of bowel dilatation that interfere with the proper identification of the adnexal area. Benefit of taking simethicone prior to do minilaparotomy for tubal resection has not been examined.

Objectives: To examine the effect of simethicone on reducing bowel interference during minilaparotomy for tubal resection.

Design: A randomized controlled trial in women, age 20-45 years, undergoing postpartum sterilization after vaginal delivery at Faculty of Medicine, Chiang Mai University hospital. The participants will be randomly assigned into one of two study groups: intervention (taking simethicone) and control (not taking simethicone). For the intervention group, each woman will take simethicone (80 mg) 2 tablet chewing with water 50 ml at 2-8 hours before surgery. Fasting at least 6 hours before surgery. For the control group, the women will receive the same standard perioperative care without taking simethicone. The primary outcome measure will be surgeon-rated operative difficulty score, which is a visual analog scale based on assess from exposure of to the operative field in visual analog scale by surgeon. The secondary outcome will be operative time and incidence of intraoperative and postoperative complications.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date March 31, 2019
Est. primary completion date February 28, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria:

- Women requesting postpartum sterilization by minilaparotomic tubal resection after vaginal delivery at Faculty of Medicine, Chiang Mai University

Exclusion Criteria:

- Pre-pregnancy BMI > 25 kg/m2

- Intraoperative general anesthesia or epidural anesthesia

- Previous abdominal surgery except for appendectomy

- Known bowel disorder including Crohn's disease, ulcerative colitis, previous bowel surgery

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Simethicone 80 MG
Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery

Locations

Country Name City State
Thailand Department of OB-GYN, Faculty of Medicine, Chiang Mai University Chiang Mai

Sponsors (1)

Lead Sponsor Collaborator
Chiang Mai University

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Operative difficulty score Operative difficulty scores will be assessed at the end of the operation by the operating surgeon. The surgeon will rate the difficulty of the operation from 0 to 10 according to the 10-cm visual analog scale with "0" represents the easiest operation and "10" represents the hardest operation. At the end of operation (within 1 hour after the completion of the operation)
Secondary Operation time (Total) The time duration from skin incision to completion of skin closure From the start of skin incision creation to the completion of skin closure (up to 2 hours)
Secondary Operation time (Intraabdominal) The time duration from first entering abdominal cavity to start closing the abdominal peritoneum. From first entering abdominal cavity to start closing the abdominal peritoneum (up to 2 hours)